Functional tyrosine kinase inhibitor profiling: A generally applicable method points to a novel role of platelet-derived growth factor receptor-β in tuberous sclerosis

Jack L. Arbiser, Baskaran Govindarajan, Xianhe Bai, Hiroaki Onda, Andrius Kazlauskas, So Dug Lim, Mahul Amin, Lena Claesson-Welsh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tumors often exhibit activation of specific tyrosine kinases, which may allow targeting of therapy through inhibition of tyrosine kinase signaling. This strategy has been used successfully in the development of STI571 (gleevec), an inhibitor of bcr-abl tyrosine kinase that has been used successfully in the treatment of chronic myelogenous leukemia. STI571 also shows activity against c-kit and platelet-derived growth factor receptor-β (PDGFRβ) tyrosine kinase signaling, thus potentially expanding the number of tumors that may respond to it. We describe a simple and rapid method to assess functional activity of tyrosine kinase signaling that is broadly applicable to tumor types. As proof of principle, we have applied it to cells that serve as models of the autosomal-dominant tumor syndrome tuberous sclerosis (TS). We found that TS model cells derived from tuberin heterozygous mice and from a human renal angiomyolipoma are highly sensitive to PDGFR antagonists and that these cells express PDGFRβ. Given that PDGFRβ signaling is inhibited by STI571, we found that SV7tert human angiomyolipoma cells are sensitive to STI571. Thus, we describe a novel but simple method of determining the functional tyrosine kinase profile of a neoplastic cell and our results suggest that STI571 might be useful in the treatment of neoplasms commonly seen in patients with TS.

Original languageEnglish (US)
Article number64237
Pages (from-to)781-786
Number of pages6
JournalAmerican Journal of Pathology
Volume161
Issue number3
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Platelet-Derived Growth Factor Receptors
Tuberous Sclerosis
Protein-Tyrosine Kinases
Angiomyolipoma
Neoplasms
bcr-abl Fusion Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Therapeutics
Kidney

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Functional tyrosine kinase inhibitor profiling : A generally applicable method points to a novel role of platelet-derived growth factor receptor-β in tuberous sclerosis. / Arbiser, Jack L.; Govindarajan, Baskaran; Bai, Xianhe; Onda, Hiroaki; Kazlauskas, Andrius; Lim, So Dug; Amin, Mahul; Claesson-Welsh, Lena.

In: American Journal of Pathology, Vol. 161, No. 3, 64237, 01.01.2002, p. 781-786.

Research output: Contribution to journalArticle

Arbiser, Jack L. ; Govindarajan, Baskaran ; Bai, Xianhe ; Onda, Hiroaki ; Kazlauskas, Andrius ; Lim, So Dug ; Amin, Mahul ; Claesson-Welsh, Lena. / Functional tyrosine kinase inhibitor profiling : A generally applicable method points to a novel role of platelet-derived growth factor receptor-β in tuberous sclerosis. In: American Journal of Pathology. 2002 ; Vol. 161, No. 3. pp. 781-786.
@article{633eaa1ae0884908904d2c7b5453de72,
title = "Functional tyrosine kinase inhibitor profiling: A generally applicable method points to a novel role of platelet-derived growth factor receptor-β in tuberous sclerosis",
abstract = "Tumors often exhibit activation of specific tyrosine kinases, which may allow targeting of therapy through inhibition of tyrosine kinase signaling. This strategy has been used successfully in the development of STI571 (gleevec), an inhibitor of bcr-abl tyrosine kinase that has been used successfully in the treatment of chronic myelogenous leukemia. STI571 also shows activity against c-kit and platelet-derived growth factor receptor-β (PDGFRβ) tyrosine kinase signaling, thus potentially expanding the number of tumors that may respond to it. We describe a simple and rapid method to assess functional activity of tyrosine kinase signaling that is broadly applicable to tumor types. As proof of principle, we have applied it to cells that serve as models of the autosomal-dominant tumor syndrome tuberous sclerosis (TS). We found that TS model cells derived from tuberin heterozygous mice and from a human renal angiomyolipoma are highly sensitive to PDGFR antagonists and that these cells express PDGFRβ. Given that PDGFRβ signaling is inhibited by STI571, we found that SV7tert human angiomyolipoma cells are sensitive to STI571. Thus, we describe a novel but simple method of determining the functional tyrosine kinase profile of a neoplastic cell and our results suggest that STI571 might be useful in the treatment of neoplasms commonly seen in patients with TS.",
author = "Arbiser, {Jack L.} and Baskaran Govindarajan and Xianhe Bai and Hiroaki Onda and Andrius Kazlauskas and Lim, {So Dug} and Mahul Amin and Lena Claesson-Welsh",
year = "2002",
month = "1",
day = "1",
doi = "10.1016/S0002-9440(10)64237-X",
language = "English (US)",
volume = "161",
pages = "781--786",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Functional tyrosine kinase inhibitor profiling

T2 - A generally applicable method points to a novel role of platelet-derived growth factor receptor-β in tuberous sclerosis

AU - Arbiser, Jack L.

AU - Govindarajan, Baskaran

AU - Bai, Xianhe

AU - Onda, Hiroaki

AU - Kazlauskas, Andrius

AU - Lim, So Dug

AU - Amin, Mahul

AU - Claesson-Welsh, Lena

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Tumors often exhibit activation of specific tyrosine kinases, which may allow targeting of therapy through inhibition of tyrosine kinase signaling. This strategy has been used successfully in the development of STI571 (gleevec), an inhibitor of bcr-abl tyrosine kinase that has been used successfully in the treatment of chronic myelogenous leukemia. STI571 also shows activity against c-kit and platelet-derived growth factor receptor-β (PDGFRβ) tyrosine kinase signaling, thus potentially expanding the number of tumors that may respond to it. We describe a simple and rapid method to assess functional activity of tyrosine kinase signaling that is broadly applicable to tumor types. As proof of principle, we have applied it to cells that serve as models of the autosomal-dominant tumor syndrome tuberous sclerosis (TS). We found that TS model cells derived from tuberin heterozygous mice and from a human renal angiomyolipoma are highly sensitive to PDGFR antagonists and that these cells express PDGFRβ. Given that PDGFRβ signaling is inhibited by STI571, we found that SV7tert human angiomyolipoma cells are sensitive to STI571. Thus, we describe a novel but simple method of determining the functional tyrosine kinase profile of a neoplastic cell and our results suggest that STI571 might be useful in the treatment of neoplasms commonly seen in patients with TS.

AB - Tumors often exhibit activation of specific tyrosine kinases, which may allow targeting of therapy through inhibition of tyrosine kinase signaling. This strategy has been used successfully in the development of STI571 (gleevec), an inhibitor of bcr-abl tyrosine kinase that has been used successfully in the treatment of chronic myelogenous leukemia. STI571 also shows activity against c-kit and platelet-derived growth factor receptor-β (PDGFRβ) tyrosine kinase signaling, thus potentially expanding the number of tumors that may respond to it. We describe a simple and rapid method to assess functional activity of tyrosine kinase signaling that is broadly applicable to tumor types. As proof of principle, we have applied it to cells that serve as models of the autosomal-dominant tumor syndrome tuberous sclerosis (TS). We found that TS model cells derived from tuberin heterozygous mice and from a human renal angiomyolipoma are highly sensitive to PDGFR antagonists and that these cells express PDGFRβ. Given that PDGFRβ signaling is inhibited by STI571, we found that SV7tert human angiomyolipoma cells are sensitive to STI571. Thus, we describe a novel but simple method of determining the functional tyrosine kinase profile of a neoplastic cell and our results suggest that STI571 might be useful in the treatment of neoplasms commonly seen in patients with TS.

UR - http://www.scopus.com/inward/record.url?scp=0036733608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036733608&partnerID=8YFLogxK

U2 - 10.1016/S0002-9440(10)64237-X

DO - 10.1016/S0002-9440(10)64237-X

M3 - Article

C2 - 12213705

AN - SCOPUS:0036733608

VL - 161

SP - 781

EP - 786

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

M1 - 64237

ER -